Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
NCT06136728
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? Is the combined treatment associated with better outcomes than the medication (dalfampridine) on its own?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Multiple Sclerosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 25 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MGH Institute of Health Professions
- Last updated on ClinicalTrials.gov
- July 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- MGH Institute of Health Professions · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.